Positive sentinel lymph node in a patient with clinical stage I vaginal cancer

por Montemorano, Lauren, Vetter, Monica Hagan, Blumenfeld, Michael, O'Malley, David M.
Publicado 2020

Phenotypic plasticity of fine root growth increases plant productivity in pine seedlings

por Wu, Rongling, Grissom, James E, McKeand, Steven E, O'Malley, David M
Publicado 2004

PARP Inhibitors in Ovarian Cancer: A Review

por O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.
Publicado 2023

Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data

por Arend, Rebecca C., O’Malley, David M., Banerjee, Susana, McLaurin, Kimmie, Davidson, Richard, Long, Gráinne H.
Publicado 2021

Overcoming the challenges of drug development in platinum-resistant ovarian cancer

por Eskander, Ramez N., Moore, Kathleen N., Monk, Bradley J., Herzog, Thomas J., Annunziata, Christina M., O’Malley, David M., Coleman, Robert L.
Publicado 2023

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

por Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.
Publicado 2021

A comprehensive overview of radioguided surgery using gamma detection probe technology

por Povoski, Stephen P, Neff, Ryan L, Mojzisik, Cathy M, O'Malley, David M, Hinkle, George H, Hall, Nathan C, Murrey, Douglas A, Knopp, Michael V, Martin, Edward W
Publicado 2009

COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies

por Monk, Bradley J., Coleman, Robert L., Moore, Kathleen N., Herzog, Thomas J., Secord, Angeles Alvarez, Matulonis, Ursula A., Slomovitz, Brian M., Guntupalli, Saketh R., O'Malley, David M.
Publicado 2020

Wound complications following vulvar excision for nonmalignant lesions

por Boyles, Glenn P., Weaver, Ashlee M., Cohn, David E., Backes, Floor J., Copeland, Larry J., Bixel, Kristin L., Fowler, Jeffrey M., O'Malley, David M., Cosgrove, Casey M.
Publicado 2021

Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer

por Piver, Rachael N., Wagner, Vincent M., Levine, Monica D., Backes, Floor J., Chambers, Laura J., Cohn, David E., Copeland, Larry J., Cosgrove, Casey M., Nagel, Christa I., O'Malley, David M., Bixel, Kristin L.
Publicado 2023

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

por O'Malley, David M., Bariani, Giovanni Mendonca, Cassier, Philippe A., Marabelle, Aurelien, Hansen, Aaron R., De Jesus Acosta, Ana, Miller, Wilson H., Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele
Publicado 2022

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

por O'Malley, David M., Neffa, Maryna, Monk, Bradley J., Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M., Bagameri, Andrea, Wang, Edward W., Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona
Publicado 2022

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

por Aghajanian, Carol, Swisher, Elizabeth M., Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A., Fleming, Gini F., Friedlander, Michael, Moore, Kathleen N., Tewari, Krishnansu S., O’Malley, David M., Chan, John K., Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H., Coleman, Robert L.
Publicado 2022

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

por Oaknin, Ana, Pothuri, Bhavana, Gilbert, Lucy, Sabatier, Renaud, Brown, Jubilee, Ghamande, Sharad, Mathews, Cara, O'Malley, David M., Kristeleit, Rebecca, Boni, Valentina, Gravina, Adriano, Banerjee, Susana, Miller, Rowan, Pikiel, Joanna, Mirza, Mansoor R., Dewal, Ninad, Antony, Grace, Dong, Yuping, Zografos, Eleftherios, Veneris, Jennifer, Tinker, Anna V.
Publicado 2023

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable...

por Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana
Publicado 2022

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA tr...

por Barretina-Ginesta, Maria-Pilar, Monk, Bradley J., Han, Sileny, Pothuri, Bhavana, Auranen, Annika, Chase, Dana M., Lorusso, Domenica, Anderson, Charles, Abadie-Lacourtoisie, Sophie, Cloven, Noelle, Braicu, Elena I., Amit, Amnon, Redondo, Andrés, Shah, Ruchit, Kebede, Nehemiah, Hawkes, Carol, Gupta, Divya, Woodward, Tatia, O’Malley, David M., González-Martín, Antonio
Publicado 2022

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as mainten...

por Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S
Publicado 2021

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease...

por Oaknin, Ana, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Amenedo Gancedo, Margarita, Fong, Peter C., Goh, Jeffrey C., O’Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García‐Donas, Jesus, Swisher, Elizabeth M., Cameron, Terri, Maloney, Lara, Goble, Sandra, Ledermann, Jonathan A., Coleman, Robert L.
Publicado 2021

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

por Gershenson, David M, Miller, Austin, Brady, William E, Paul, James, Carty, Karen, Rodgers, William, Millan, David, Coleman, Robert L, Moore, Kathleen N, Banerjee, Susana, Connolly, Kate, Secord, Angeles Alvarez, O'Malley, David M, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robert L, Herrington, C Simon, Huang, Helen Q, Wenzel, Lari, Gourley, Charlie
Publicado 2022

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

por O’Cearbhaill, Roisin E., Pérez-Fidalgo, Jose-Alejandro, Monk, Bradley J., Tusquets, Ignacio, McCormick, Colleen, Fuentes, Jose, Moore, Richard G., Vulsteke, Christof, Shahin, Mark S., Forget, Frédéric, Bradley, William H., Hietanen, Sakari, O’Malley, David M., Dørum, Anne, Slomovitz, Brian M., Baumann, Klaus, Selle, Frédéric, Calvert, Paula M., Artioli, Grazia, Levy, Tally, Kumar, Aalok, Malinowska, Izabela A., Li, Yong, Gupta, Divya, González-Martín, Antonio
Publicado 2022